Minerva Neuroscie (NERV)

$8.00 +1.99 (33.11%)
Market Cap 260.08M
Revenue (ttm) 0.00
Net Income (ttm) 1.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 588,400
Avg Vol 113,396
Day's Range N/A - N/A
Shares Out 43.27M
Stochastic %K 95%
Beta -0.31
Analysts Hold
Price Target $4.50

Company Profile

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of negative symptoms in patients with schizophrenia. The company also has exclusive rights to develop and commercialize MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of Parkinson's disease and other neur...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 600 7373
Address:
1500 District Avenue, Burlington, United States
Stock_Catcher
Stock_Catcher Mar. 10 at 2:16 AM
Treasure Tuesday Watchlist Pt. 5 $IBRX $RLMD $GSIW $HIMS $NERV Let's Find Another Supernova Tomorrow
0 · Reply
Invest2live
Invest2live Mar. 9 at 7:29 PM
$NERV 235% already; get in $HUMA and $AKBA after your DD.
0 · Reply
topstockalerts
topstockalerts Mar. 9 at 7:19 PM
$NERV biotech that previously moved on drug development updates and restructuring plans. These setups can reawaken when traders anticipate new clinical catalysts or funding clarity. Does speculation return?
0 · Reply
JonathanV
JonathanV Mar. 9 at 5:02 PM
$NERV why?
0 · Reply
Elaine_Shrimp
Elaine_Shrimp Mar. 9 at 4:58 PM
$NERV now is distributing stage
0 · Reply
Mg_1970
Mg_1970 Mar. 9 at 4:34 PM
$NERV 😱😍😍😎
0 · Reply
topstockalerts
topstockalerts Mar. 9 at 3:42 PM
$NERV Following this closely as it continues to build momentum. Buyers are in control. Could be more upside ahead.
0 · Reply
Stock_Catcher
Stock_Catcher Mar. 9 at 2:21 PM
$NERV thin one hitting my scanner
0 · Reply
Elaine_Shrimp
Elaine_Shrimp Mar. 9 at 2:05 PM
$NERV .🤫
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 4 at 7:36 PM
$NERV Current Stock Price: $6.81
0 · Reply
Latest News on NERV
Minerva Neurosciences to Participate in The Citizens Life Sciences Conference

Mar 4, 2026, 7:00 AM EST - 5 days ago

Minerva Neurosciences to Participate in The Citizens Life Sciences Conference

Minerva Neurosciences, Inc. (NERV) Discusses Roluperidone as a Potential First Treatment for Negative Symptoms of Schizophrenia Transcript

Feb 3, 2026, 7:40 PM EST - 4 weeks ago

Minerva Neurosciences, Inc. (NERV) Discusses Roluperidone as a Potential First Treatment for Negative Symptoms of Schizophrenia Transcript

Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026

Jan 26, 2026, 7:00 AM EST - 6 weeks ago

Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026

Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors

Nov 19, 2025, 8:30 AM EST - 3 months ago

Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors

Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates

Nov 5, 2025, 7:30 AM EST - 4 months ago

Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates

Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved

Oct 21, 2025, 8:00 AM EDT - 4 months ago

Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved

Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results

Aug 14, 2025, 4:35 PM EDT - 7 months ago

Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results

Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates

May 13, 2025, 7:30 AM EDT - 10 months ago

Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates

Feb 25, 2025, 7:00 AM EST - 1 year ago

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates

Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates

Nov 5, 2024, 7:30 AM EST - 1 year ago

Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates

Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates

May 1, 2024, 7:30 AM EDT - 2 years ago

Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates

US FDA declines to approve Minerva Neurosciences' schizophrenia drug

Feb 27, 2024, 8:14 AM EST - 2 years ago

US FDA declines to approve Minerva Neurosciences' schizophrenia drug

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates

Feb 22, 2024, 7:00 AM EST - 2 years ago

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates

Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates

Nov 7, 2023, 7:30 AM EST - 2 years ago

Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates

Minerva Neurosciences: There's Probably Time For One More Rally

Aug 23, 2023, 4:05 AM EDT - 2 years ago

Minerva Neurosciences: There's Probably Time For One More Rally

Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates

Aug 1, 2023, 7:30 AM EDT - 2 years ago

Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates

Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market

Jun 28, 2023, 8:30 AM EDT - 2 years ago

Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market

Minerva Neurosciences: Up About 250 Percent Since April With An FDA Catalyst Ahead

May 19, 2023, 5:34 PM EDT - 3 years ago

Minerva Neurosciences: Up About 250 Percent Since April With An FDA Catalyst Ahead

Minerva Neurosciences, Inc. (NERV) Q1 2023 Earnings Call Transcript

May 15, 2023, 11:26 AM EDT - 3 years ago

Minerva Neurosciences, Inc. (NERV) Q1 2023 Earnings Call Transcript

Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates

May 15, 2023, 7:30 AM EDT - 3 years ago

Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates

Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

May 10, 2023, 8:00 AM EDT - 3 years ago

Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023

May 8, 2023, 8:30 AM EDT - 3 years ago

Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023

Minerva Neurosciences, Inc. (NERV) Q4 2022 Earnings Call Transcript

Mar 8, 2023, 11:31 AM EST - 3 years ago

Minerva Neurosciences, Inc. (NERV) Q4 2022 Earnings Call Transcript

Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates

Mar 8, 2023, 7:30 AM EST - 3 years ago

Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates

Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023

Mar 1, 2023, 8:30 AM EST - 3 years ago

Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023

Minerva Neurosciences, Inc. (NERV) Q3 2022 Earnings Call Transcript

Nov 9, 2022, 10:02 AM EST - 3 years ago

Minerva Neurosciences, Inc. (NERV) Q3 2022 Earnings Call Transcript

Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates

Nov 9, 2022, 8:00 AM EST - 3 years ago

Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates

Minerva Neurosciences to Report Third Quarter 2022 Financial Results and Business Updates on November 9, 2022

Nov 2, 2022, 8:30 AM EDT - 3 years ago

Minerva Neurosciences to Report Third Quarter 2022 Financial Results and Business Updates on November 9, 2022

Minerva Neurosciences to request meeting with FDA about schizophrenia drug

Oct 17, 2022, 8:51 AM EDT - 3 years ago

Minerva Neurosciences to request meeting with FDA about schizophrenia drug

Minerva Neurosciences Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Oct 17, 2022, 8:30 AM EDT - 3 years ago

Minerva Neurosciences Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Minerva Neurosciences Announces Listing Transfer to Nasdaq Capital Market

Sep 9, 2022, 4:05 PM EDT - 3 years ago

Minerva Neurosciences Announces Listing Transfer to Nasdaq Capital Market

Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia

Aug 22, 2022, 8:00 AM EDT - 3 years ago

Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia

Minerva Neurosciences Reports Second Quarter 2022 Financial Results and Business Updates

Aug 9, 2022, 8:00 AM EDT - 3 years ago

Minerva Neurosciences Reports Second Quarter 2022 Financial Results and Business Updates

Minerva Neurosciences Reports First Quarter 2022 Financial Results and Business Updates

May 4, 2022, 8:30 AM EDT - 4 years ago

Minerva Neurosciences Reports First Quarter 2022 Financial Results and Business Updates

Minerva Outlines Next Steps For US Application For Schizophrenia Candidate

Apr 7, 2022, 1:01 PM EDT - 4 years ago

Minerva Outlines Next Steps For US Application For Schizophrenia Candidate

Minerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of a New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Apr 7, 2022, 8:30 AM EDT - 4 years ago

Minerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of a New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Minerva Neurosciences Reports Fourth Quarter 2021 Financial Results and Business Updates

Mar 1, 2022, 7:30 AM EST - 4 years ago

Minerva Neurosciences Reports Fourth Quarter 2021 Financial Results and Business Updates

Minerva Neurosciences Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia Bulletin

Feb 28, 2022, 8:30 AM EST - 4 years ago

Minerva Neurosciences Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia Bulletin

Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q3 2021 Results - Earnings Call Transcript

Nov 8, 2021, 2:11 PM EST - 4 years ago

Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q3 2021 Results - Earnings Call Transcript

Minerva Neurosciences Reports Third Quarter 2021 Financial Results and Business Updates

Nov 8, 2021, 7:30 AM EST - 4 years ago

Minerva Neurosciences Reports Third Quarter 2021 Financial Results and Business Updates

Minerva Neurosciences Announces FDA Recommendation for Type C Meeting to Discuss Evidence for Use of Roluperidone as Monotherapy for the Treatment of Negative Symptoms in Patients with Schizophrenia in Advance of Potential NDA Submission

Nov 3, 2021, 8:30 AM EDT - 4 years ago

Minerva Neurosciences Announces FDA Recommendation for Type C Meeting to Discuss Evidence for Use of Roluperidone as Monotherapy for the Treatment of Negative Symptoms in Patients with Schizophrenia in Advance of Potential NDA Submission

Minerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on November 8

Nov 1, 2021, 8:30 AM EDT - 4 years ago

Minerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on November 8

Minerva Neurosciences Announces Promotion of Geoff Race to President

Oct 11, 2021, 8:30 AM EDT - 4 years ago

Minerva Neurosciences Announces Promotion of Geoff Race to President

Minerva Posts Positive Bioequivalence Results For Schizophrenia Candidate Formulations

Sep 30, 2021, 10:32 AM EDT - 4 years ago

Minerva Posts Positive Bioequivalence Results For Schizophrenia Candidate Formulations

Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia

Sep 30, 2021, 8:30 AM EDT - 4 years ago

Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia

Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q2 2021 Results - Earnings Call Transcript

Aug 2, 2021, 12:19 PM EDT - 5 years ago

Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q2 2021 Results - Earnings Call Transcript

Minerva Neurosciences Reports Second Quarter 2021 Financial Results and Business Updates

Aug 2, 2021, 7:30 AM EDT - 5 years ago

Minerva Neurosciences Reports Second Quarter 2021 Financial Results and Business Updates

Minerva Neurosciences to Report Second Quarter 2021 Financial Results and Business Updates on August 2, 2021

Jul 26, 2021, 8:30 AM EDT - 5 years ago

Minerva Neurosciences to Report Second Quarter 2021 Financial Results and Business Updates on August 2, 2021

Minerva Neurosciences to Present at JMP Securities Life Sciences Conference

Jun 10, 2021, 8:30 AM EDT - 5 years ago

Minerva Neurosciences to Present at JMP Securities Life Sciences Conference

Minerva Neurosciences to Present at Jefferies Virtual Healthcare Conference

May 28, 2021, 8:00 AM EDT - 5 years ago

Minerva Neurosciences to Present at Jefferies Virtual Healthcare Conference

Stock_Catcher
Stock_Catcher Mar. 10 at 2:16 AM
Treasure Tuesday Watchlist Pt. 5 $IBRX $RLMD $GSIW $HIMS $NERV Let's Find Another Supernova Tomorrow
0 · Reply
Invest2live
Invest2live Mar. 9 at 7:29 PM
$NERV 235% already; get in $HUMA and $AKBA after your DD.
0 · Reply
topstockalerts
topstockalerts Mar. 9 at 7:19 PM
$NERV biotech that previously moved on drug development updates and restructuring plans. These setups can reawaken when traders anticipate new clinical catalysts or funding clarity. Does speculation return?
0 · Reply
JonathanV
JonathanV Mar. 9 at 5:02 PM
$NERV why?
0 · Reply
Elaine_Shrimp
Elaine_Shrimp Mar. 9 at 4:58 PM
$NERV now is distributing stage
0 · Reply
Mg_1970
Mg_1970 Mar. 9 at 4:34 PM
$NERV 😱😍😍😎
0 · Reply
topstockalerts
topstockalerts Mar. 9 at 3:42 PM
$NERV Following this closely as it continues to build momentum. Buyers are in control. Could be more upside ahead.
0 · Reply
Stock_Catcher
Stock_Catcher Mar. 9 at 2:21 PM
$NERV thin one hitting my scanner
0 · Reply
Elaine_Shrimp
Elaine_Shrimp Mar. 9 at 2:05 PM
$NERV .🤫
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 4 at 7:36 PM
$NERV Current Stock Price: $6.81
0 · Reply
kshonstocks
kshonstocks Mar. 2 at 6:17 PM
$NERV terrific ibd-99 A https://research.investors.com/stock-quotes/nasdaq-minerva-neurosciences-nerv.htm $NERV
0 · Reply
kshonstocks
kshonstocks Mar. 2 at 5:53 PM
like this $NERV chart and action
0 · Reply
AshMomentum
AshMomentum Feb. 18 at 7:02 AM
$NERV Minerva Neurosciences develops CNS therapies, facing clinical-stage pipeline with high failure risk and binary catalysts [citation:historical].
0 · Reply
6GodEnergy
6GodEnergy Feb. 17 at 6:29 PM
$NERV $ZIM $CGNX $ZEPP •[]•
0 · Reply
6GodEnergy
6GodEnergy Feb. 17 at 4:12 PM
$CPS $QNRX $NERV $LFS ~~~>
0 · Reply
S2K_TP
S2K_TP Feb. 11 at 4:45 AM
$NERV on watch
0 · Reply
VolArbTrader
VolArbTrader Feb. 11 at 4:24 AM
$NERV Neuroscience-focused biotech; CNS drug development carries exceptionally high failure rates and long trial timelines, making valuation highly sensitive to clinical readouts.
0 · Reply
Mg_1970
Mg_1970 Feb. 10 at 5:26 PM
$NERV Uhmm... this will fly 😎😍💪 my avg price is about 4.15
0 · Reply
EliteTradingGoat
EliteTradingGoat Feb. 10 at 5:18 PM
$NERV OOOOUUTTTTTT +33%
0 · Reply
Mg_1970
Mg_1970 Feb. 10 at 4:02 PM
$AREB Take an eye at $NERV 😎😎 if it breaks 5.85
0 · Reply
trading_momentum_x
trading_momentum_x Feb. 10 at 11:11 AM
$NERV huge pop and fade play on watch. Bounced off the POC line and large volume shelf and saw resistance near 5.70 area, almost filling the gap near 6$. Has room and relative volume too see 6.90 and 8.7. Price is currently over all local MAs.
0 · Reply
FonsieTrader
FonsieTrader Feb. 10 at 9:46 AM
$NERV swing trade
0 · Reply